Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
OGEN Oragenics Inc
- Stocks
- Healthcare
- NYSEAMERICAN: OGEN
Price (delayed)
$0.1912
Market cap
$4.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.12
Enterprise value
$3.24M
Oragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against
Highlights
OGEN's EPS has surged by 87% year-on-year and by 30% since the previous quarter
Oragenics's net income has increased by 49% YoY and by 2.2% from the previous quarter
Oragenics's equity has soared by 165% from the previous quarter but it has plunged by 95% YoY
The company's quick ratio has surged by 80% QoQ but it has shrunk by 60% YoY
The gross profit has dropped by 100% year-on-year
Oragenics's revenue has shrunk by 100% YoY
Key stats
What are the main financial stats of OGEN
Market
Valuations
Earnings
Shares outstanding
21.48M
Market cap
$4.11M
Enterprise value
$3.24M
Price to earnings (P/E)
N/A
Price to book (P/B)
29.82
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$10.12M
Net income
-$10.33M
EBIT
-$10.11M
EBITDA
-$10.11M
Free cash flow
-$7.65M
Per share
Balance sheet
Liquidity
EPS
-$1.12
EPS diluted
-$1.12
Free cash flow per share
-$0.42
Book value per share
$0.01
Revenue per share
$0
TBVPS
$0.21
Total assets
$3.87M
Total liabilities
$3.73M
Debt
$2.55M
Equity
$137,688
Working capital
$137,688
Debt to equity
18.55
Current ratio
1.04
Quick ratio
0.92
Net debt/EBITDA
0.09
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-311.8%
Return on equity
-954.7%
Return on invested capital
N/A
Return on capital employed
-7,344.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OGEN stock price
How has the Oragenics stock price performed over time
Intraday
6.22%
1 week
6.64%
1 month
0.1%
1 year
-87.25%
YTD
-48.23%
QTD
-8.95%
Financial performance
How have Oragenics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$10.12M
Net income
-$10.33M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
Oragenics's revenue has shrunk by 100% YoY
OGEN's operating income has surged by 51% year-on-year and by 4.1% since the previous quarter
Oragenics's net income has increased by 49% YoY and by 2.2% from the previous quarter
Price vs fundamentals
How does OGEN's price correlate with its fundamentals
Growth
What is Oragenics's growth rate over time
Valuation
What is Oragenics stock price valuation
P/E
N/A
P/B
29.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OGEN's EPS has surged by 87% year-on-year and by 30% since the previous quarter
Oragenics's equity has soared by 165% from the previous quarter but it has plunged by 95% YoY
Oragenics's revenue has shrunk by 100% YoY
Efficiency
How efficient is Oragenics business performance
OGEN's ROE has plunged by 130% YoY and by 54% from the previous quarter
OGEN's ROA is up by 4.7% since the previous quarter and by 4.4% year-on-year
Dividends
What is OGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OGEN.
Financial health
How did Oragenics financials performed over time
The total assets is 3.7% more than the total liabilities
The total assets has soared by 163% from the previous quarter and by 9% YoY
The total liabilities has soared by 122% from the previous quarter
Oragenics's equity has soared by 165% from the previous quarter but it has plunged by 95% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.